Literature DB >> 28623515

Pancreatic ductal adenocarcinoma: metastatic disease.

A J Muñoz Martín1, J Adeva2, J Martínez-Galán3, J J Reina4, M Hidalgo5.   

Abstract

The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called "therapeutic sequencing" has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient's characteristics.

Entities:  

Keywords:  Management; Metastatic; Pancreatic ductal adenocarcinoma; Re-evaluation; Treatment sequencing

Mesh：

Year:  2017        PMID： 28623515     DOI： 10.1007/s12094-017-1690-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  25 in total

1.  A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.

Authors:  Peter J Hosein; Gilberto de Lima Lopes; Vitor H Pastorini; Christina Gomez; Jessica Macintyre; Gloria Zayas; Isildinha Reis; Alberto J Montero; Jaime R Merchan; Caio M Rocha Lima
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

Review 2.  Treatment of metastatic pancreatic adenocarcinoma: a review.

Authors:  Ramya Thota; James M Pauff; Jordan D Berlin
Journal:  Oncology (Williston Park)       Date:  2014-01       Impact factor: 2.990

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.

Authors:  Renata D Peixoto; Maria Ho; Daniel J Renouf; Howard J Lim; Sharlene Gill; Jenny Y Ruan; Winson Y Cheung
Journal:  Am J Clin Oncol       Date:  2017-10       Impact factor: 2.339

5.  Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.

Authors:  M L Rothenberg; N J Meropol; E A Poplin; E Van Cutsem; S Wadler
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

Review 6.  Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.

Authors:  Massimo Di Maio; Emilio Bria; Giuseppe L Banna; Fabio Puglisi; Marina C Garassino; Domenica Lorusso; Francesco Perrone
Journal:  Anticancer Drugs       Date:  2013-02       Impact factor: 2.248

7.  Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

Authors:  A P Venook; M J Egorin; G L Rosner; D Hollis; S Mani; M Hawkins; J Byrd; R Hohl; D Budman; N J Meropol; M J Ratain
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

Review 8.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

Authors:  Manuel Hidalgo; Stefano Cascinu; Jörg Kleeff; Roberto Labianca; J-Matthias Löhr; John Neoptolemos; Francisco X Real; Jean-Luc Van Laethem; Volker Heinemann
Journal:  Pancreatology       Date:  2014-10-17       Impact factor: 3.996

9.  PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.

Authors:  M Reni; S Cereda; E Mazza; P Passoni; R Nicoletti; G Balzano; A Zerbi; P G Arcidiacono; C Staudacher; V Di Carlo
Journal:  Am J Clin Oncol       Date:  2008-04       Impact factor: 2.339

10.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245
View more
  5 in total

1.  Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Amir A Borhani; Rohit Dewan; Alessandro Furlan; Natalie Seiser; Amer H Zureikat; Aatur D Singhi; Brian Boone; Nathan Bahary; Melissa E Hogg; Michael Lotze; Herbert J Zeh; Mitchell E Tublin
Journal:  AJR Am J Roentgenol       Date:  2019-12-04       Impact factor: 3.959

Review 2.  Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models.

Authors:  Ulrich H Weidle; Fabian Birzele; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

3.  Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy.

Authors:  Jing-Yu Qian; Yu-Lin Tan; Yang Zhang; Yong-Fei Yang; Xiao-Qiang Li
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

4.  BAG3 regulates stability of IL-8 mRNA via interplay between HuR and miR-4312 in PDACs.

Authors:  Chao Li; Jing-Yi Jiang; Jia-Mei Wang; Jia Sun; Ming-Xin An; Si Li; Jing Yan; Hua-Qin Wang
Journal:  Cell Death Dis       Date:  2018-08-28       Impact factor: 8.469

Review 5.  From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer.

Authors:  Andrés Muñoz Martín; Manuel Hidalgo; Rafael Alvarez; Virginia Arrazubi; Joaquina Martínez-Galán; Mercedes Salgado; Teresa Macarulla; Alfredo Carrato
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.